Graded per the Lee 2014 criteria.¹¹ 

Defined as investigator-identified neurological AEs related to liso-cel and graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03.

Defined as grade ≥3 central laboratory results at 35 days after liso-cel infusion or after the start of the last chemotherapy in the SOC arm. Prolonged cytopenia was assessed at the study day 64 visit for patients in the liso-cel arm (35 days after liso-cel infusion) or 35 days after the start of the last cycle of chemotherapy, including high-dose chemotherapy, for patients in the SOC arm. A window of ±6 days around these target dates was considered; within this window, the closest central laboratory assessment to the target date was used, and in case 2 assessments within the same window were equidistant from the target date, the worst result was taken. Laboratory assessments performed after starting a new antineoplastic therapy were not considered for analysis.

In the liso-cel arm, poststudy day 64 laboratory results were available for 34, 33, and 11 patients with grade ≥3 neutropenia, thrombocytopenia, and anemia, respectively. In the SOC arm, poststudy day 64 laboratory results were available for 1, 0, and 1 patient with grade ≥3 neutropenia, thrombocytopenia, and anemia, respectively. Recovery to grade ≤2 cytopenia was assessed on days 35 and 62 days after the initial prolonged cytopenia assessment and at the end of the study.